Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HCV Franchise by Quarter
Total HCV Franchise (legacy sub-franchise breakout) ($M) ($M)
Gilead Sciences Total HCV Franchise: $432M in Q4 2023, down 1.6% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HCV Franchise (legacy sub-franchise breakout) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 432 | -1.6% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 438 | -16.4% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 452 | +0.9% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 445 | +11.5% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 439 | +11.7% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 524 | +22.1% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 448 | -18.4% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 399 | -21.8% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 393 | -7.1% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 429 | -7.5% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 549 | +22.5% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 510 | -30.0% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 423 | -32.9% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 464 | – | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 448 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 729 | – | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 630 | – | Form 8-K (exhibit991earningspressrel.htm, filed 2021-02-04) ↗ |
Breakdown
What makes up total HCV Franchise
- Total HCV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)251 · Q4 2023
- Total HCV Franchise (legacy sub-franchise breakout) — Europe sales ($M)84 · Q4 2023
- Total HCV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)97 · Q4 2023
- Total HCV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%)12.0% · Q4 2022
- Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) ($M)16 · Q4 2023
- Vosevi (sofosbuvir / velpatasvir / voxilaprevir — legacy breakout) ($M)45 · Q3 2020
- Other HCV (Sovaldi — legacy breakout) ($M)37 · Q4 2023
Cite this data
StockData. (2026). Gilead Sciences Total HCV Franchise ($M), quarterly Q4 2019–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hcv-total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.